(Q37618995)

21 August 2017

1 reference

title

Systematic review of economic evidence for the detection, diagnosis, treatment, and follow-up of colorectal cancer in the United Kingdom (English)

1 reference

21 August 2017

1 reference

1 reference

1 reference

Alan Brennan

3

0 references

author name string

Paul Tappenden

series ordinal

1

1 reference

21 August 2017

Jim Chilcott

series ordinal

2

1 reference

21 August 2017

Hazel Pilgrim

series ordinal

4

1 reference

21 August 2017

publication date

1 October 2009

1 reference

International Journal of Technology Assessment in Health Care

21 August 2017

published in

1 reference

21 August 2017

volume

25

1 reference

21 August 2017

issue

4

1 reference

21 August 2017

page(s)

470-478

1 reference

Economic evaluation of laparoscopic surgery for colorectal cancer

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990407

The cost of screening for colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990407

Options for screening for colorectal cancer in the Royal Air Force: a cost-effectiveness evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990407

Flexible sigmoidoscopy in general practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990407

The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990407

Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990407

Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990407

Option appraisal of population-based colorectal cancer screening programmes in England

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990407

Mature results from three large controlled studies with raltitrexed ('Tomudex').

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990407

Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990407

Effectiveness of preoperative staging in rectal cancer: digital rectal examination, endoluminal ultrasound or magnetic resonance imaging?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990407

Cost of quality management and information provision for screening: colorectal cancer screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990407

Hepatic resection for colorectal liver metastases: A cost-effectiveness analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990407

Cost effectiveness analysis of intensive versus conventional follow up after curative resection for colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990407

A prospective case-matched comparison of clinical and financial outcomes of open versus laparoscopic colorectal resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990407

Transanal endoscopic microsurgery--impact on the practice of a colorectal surgeon in a district general hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990407

Risk-stratified intensive follow up for treated colorectal cancer - realistic and cost saving?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990407

The influence of an enhanced recovery programme on clinical outcomes, costs and quality of life after surgery for colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990407

Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990407

Randomized clinical trial comparing laparoscopic and open surgery for colorectal cancer within an enhanced recovery programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990407

Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990407

Cost savings in mass population screening for colorectal cancer resulting from the early detection and excision of adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990407

The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990407

Costs and consequences of different chemotherapy regimens in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990407

Short-term costs of conventional vs laparoscopic assisted surgery in patients with colorectal cancer (MRC CLASICC trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990407

The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990407

Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990407

Filtering strategies in mass population screening for colorectal cancer: an economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990407

An economic evaluation of oxaliplatin for the adjuvant treatment of colon cancer in the United Kingdom (UK)

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990407

7 January 2021

Faecal occult blood screening for colorectal cancer: is it cost-effective?

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990407

7 January 2021

Is an immunological faecal occult blood test better than Haemoccult? A cost-benefit study

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990407

7 January 2021

Cost-effectiveness of screening for colorectal cancer: evidence from the Nottingham faecal occult blood trial

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990407

7 January 2021

Cost analysis of transanal endoscopic microsurgery for rectal tumours

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990407

7 January 2021

Rehydration of guaiac-based faecal occult blood tests in mass screening for colorectal cancer. An economic perspective

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990407

7 January 2021

Preoperative intensive, community-based vs. traditional stoma education: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS0266462309990407

7 January 2021

10.1017/S0266462309990407

Identifiers

DOI

1 reference

21 August 2017

1 reference